Literature DB >> 27058351

Inflammation, immune activation, and cardiovascular disease in HIV.

Eric Nou1, Janet Lo, Steven K Grinspoon.   

Abstract

Cardiovascular disease is one of the leading causes of morbidity and mortality in people living with HIV. Several epidemiological studies have shown an increased risk of myocardial infarction and stroke compared to uninfected controls. Although traditional risk factors contribute to this increased risk of cardiovascular disease, HIV-specific mechanisms likely also play a role. Systemic inflammation has been linked to cardiovascular disease in several populations suffering from chronic inflammation, including people living with HIV. Although antiretroviral therapy reduces immune activation, levels of inflammatory markers remain elevated compared to uninfected controls. The causes of this sustained immune response are likely multifactorial and incompletely understood. In this review, we summarize the evidence describing the relationship between inflammation and cardiovascular disease and discuss potential anti-inflammatory treatment options for cardiometabolic disease in people living with HIV.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27058351      PMCID: PMC4889507          DOI: 10.1097/QAD.0000000000001109

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  192 in total

1.  Reduced CD14 expression on classical monocytes and vascular endothelial adhesion markers independently associate with carotid artery intima media thickness in chronically HIV-1 infected adults on virologically suppressive anti-retroviral therapy.

Authors:  Jason D Barbour; Emilie C Jalbert; Dominic C Chow; Louie Mar A Gangcuangco; Philip J Norris; Sheila M Keating; John Heitman; Lorna Nagamine; Todd Seto; Lishomwa C Ndhlovu; Beau K Nakamoto; Howard N Hodis; Nisha I Parikh; Cecilia M Shikuma
Journal:  Atherosclerosis       Date:  2013-10-31       Impact factor: 5.162

2.  Plasma levels of soluble CD14 independently predict mortality in HIV infection.

Authors:  Netanya G Sandler; Handan Wand; Annelys Roque; Matthew Law; Martha C Nason; Daniel E Nixon; Court Pedersen; Kiat Ruxrungtham; Sharon R Lewin; Sean Emery; James D Neaton; Jason M Brenchley; Steven G Deeks; Irini Sereti; Daniel C Douek
Journal:  J Infect Dis       Date:  2011-01-20       Impact factor: 5.226

3.  Plasma cholesterol efflux capacity from human THP-1 macrophages is reduced in HIV-infected patients: impact of HAART.

Authors:  Petra El Khoury; Mathilde Ghislain; Elise F Villard; Wilfried Le Goff; Caroline Lascoux-Combe; Patrick Yeni; Laurence Meyer; Corinne Vigouroux; Cécile Goujard; Maryse Guerin
Journal:  J Lipid Res       Date:  2015-01-08       Impact factor: 5.922

4.  High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment.

Authors:  Veronica D Gonzalez; Karolin Falconer; Kim G Blom; Olle Reichard; Birgitte Mørn; Alex Lund Laursen; Nina Weis; Annette Alaeus; Johan K Sandberg
Journal:  J Virol       Date:  2009-08-26       Impact factor: 5.103

5.  Coronary calcium as a predictor of coronary events in four racial or ethnic groups.

Authors:  Robert Detrano; Alan D Guerci; J Jeffrey Carr; Diane E Bild; Gregory Burke; Aaron R Folsom; Kiang Liu; Steven Shea; Moyses Szklo; David A Bluemke; Daniel H O'Leary; Russell Tracy; Karol Watson; Nathan D Wong; Richard A Kronmal
Journal:  N Engl J Med       Date:  2008-03-27       Impact factor: 91.245

6.  Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study.

Authors:  Meagan O'Brien; Emilie Montenont; Liang Hu; Michael A Nardi; Vanessa Valdes; Michael Merolla; Gabrielle Gettenberg; Karen Cavanagh; Judith A Aberg; Nina Bhardwaj; Jeffrey S Berger
Journal:  J Acquir Immune Defic Syndr       Date:  2013-07-01       Impact factor: 3.731

7.  Impairment of the intestinal barrier is evident in untreated but absent in suppressively treated HIV-infected patients.

Authors:  H-J Epple; T Schneider; H Troeger; D Kunkel; K Allers; V Moos; M Amasheh; C Loddenkemper; M Fromm; M Zeitz; J-D Schulzke
Journal:  Gut       Date:  2008-10-20       Impact factor: 23.059

Review 8.  HIV and coronary heart disease: time for a better understanding.

Authors:  Franck Boccara; Sylvie Lang; Catherine Meuleman; Stephane Ederhy; Murielle Mary-Krause; Dominique Costagliola; Jacqueline Capeau; Ariel Cohen
Journal:  J Am Coll Cardiol       Date:  2013-02-05       Impact factor: 24.094

9.  Serum oxidized low-density lipoprotein decreases in response to statin therapy and relates independently to reductions in coronary plaque in patients with HIV.

Authors:  Eric Nou; Michael T Lu; Sara E Looby; Kathleen V Fitch; Elli A Kim; Hang Lee; Udo Hoffmann; Steven K Grinspoon; Janet Lo
Journal:  AIDS       Date:  2016-02-20       Impact factor: 4.177

10.  Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.

Authors:  Signe Westring Worm; Caroline Sabin; Rainer Weber; Peter Reiss; Wafaa El-Sadr; Francois Dabis; Stephane De Wit; Matthew Law; Antonella D'Arminio Monforte; Nina Friis-Møller; Ole Kirk; Eric Fontas; Ian Weller; Andrew Phillips; Jens Lundgren
Journal:  J Infect Dis       Date:  2010-02-01       Impact factor: 5.226

View more
  63 in total

1.  Costs and cost-effectiveness of HIV/noncommunicable disease integration in Africa: from theory to practice.

Authors:  Rachel Nugent; Ruanne V Barnabas; Ilya Golovaty; Brianna Osetinsky; D Allen Roberts; Cristina Bisson; Lauren Courtney; Pragna Patel; Gerald Yonga; David Watkins
Journal:  AIDS       Date:  2018-07-01       Impact factor: 4.177

2.  Comprehensive assessment of the arginine pathway and its relationship to inflammation in HIV.

Authors:  Sahera Dirajlal-Fargo; Khurshid Alam; Abdus Sattar; Manjusha Kulkarni; Nicholas Funderburg; Wai Hong Wilson; Grace A McComsey
Journal:  AIDS       Date:  2017-02-20       Impact factor: 4.177

3.  COMT Val158Met Polymorphism, Cardiometabolic Risk, and Nadir CD4 Synergistically Increase Risk of Neurocognitive Impairment in Men Living With HIV.

Authors:  Rowan Saloner; Maria J Marquine; Erin E Sundermann; Suzi Hong; John Allen McCutchan; Ronald J Ellis; Robert K Heaton; Igor Grant; Mariana Cherner
Journal:  J Acquir Immune Defic Syndr       Date:  2019-08-15       Impact factor: 3.731

4.  Association of Low CD4/CD8 Ratio With Adverse Cardiac Mechanics in Lymphopenic HIV-Infected Adults.

Authors:  Arjun Sinha; Harry Mystakelis; Adovich S Rivera; Maura Manion; Elizabeth Laidlaw; Yolanda Mejia; Adam Rupert; Greg Robby; Virginia Sheikh; Irini Sereti; Matthew J Feinstein
Journal:  J Acquir Immune Defic Syndr       Date:  2020-12-01       Impact factor: 3.731

Review 5.  HIV and Aging in Mainland China: Implications for Control and Prevention Research.

Authors:  Na He; Yingying Ding; Jing Li; Shiying Yuan; Lulu Xu; Shijie Qiao; Xiaohui Xu; Bowen Zhu; Ruizi Shi; John P Barile; Frank Y Wong
Journal:  Curr HIV/AIDS Rep       Date:  2019-12       Impact factor: 5.071

6.  Cardiovascular Risk Prediction Functions Underestimate Risk in HIV Infection.

Authors:  Virginia A Triant; Jeremiah Perez; Susan Regan; Joseph M Massaro; James B Meigs; Steven K Grinspoon; Ralph B D'Agostino
Journal:  Circulation       Date:  2018-02-14       Impact factor: 29.690

7.  The Relationship Between Latent Tuberculosis Infection and Acute Myocardial Infarction.

Authors:  Moises A Huaman; Eduardo Ticona; Gustavo Miranda; Richard J Kryscio; Raquel Mugruza; Ernesto Aranda; Paola L Rondan; David Henson; Cesar Ticona; Timothy R Sterling; Carl J Fichtenbaum; Beth A Garvy
Journal:  Clin Infect Dis       Date:  2018-03-05       Impact factor: 9.079

8.  Intracellular HIV-1 RNA and CD4+ T-cell activation in patients starting antiretrovirals.

Authors:  Ramy El-Diwany; Florian P Breitwieser; Mary Soliman; Alyza M Skaist; Geetha Srikrishna; Joel N Blankson; Stuart C Ray; Sarah J Wheelan; David L Thomas; Ashwin Balagopal
Journal:  AIDS       Date:  2017-06-19       Impact factor: 4.177

9.  NOVEL MECHANISMS AND ANTI-INFLAMMATORY STRATEGIES TO REDUCE CARDIOVASCULAR RISK IN HUMAN IMMUNODEFICIENCY VIRUS.

Authors:  Steven Grinspoon
Journal:  Trans Am Clin Climatol Assoc       Date:  2018

10.  Increased Mortality After Tuberculosis Treatment Completion in Persons Living With Human Immunodeficiency Virus in Latin America.

Authors:  Serena P Koenig; Ahra Kim; Bryan E Shepherd; Carina Cesar; Valdilea Veloso; Claudia P Cortes; Denis Padgett; Brenda Crabtree-Ramírez; Eduardo Gotuzzo; Catherine C McGowan; Timothy R Sterling; Jean W Pape
Journal:  Clin Infect Dis       Date:  2020-06-24       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.